Screening for prostate cancer with prostate-specific antigen: beware the biases

Coley, 1995, Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II. Early detection strategies, Urology, 46, 121, 10.1016/S0090-4295(99)80181-2 1991 www.cua.org, June 1992. Chamberlain, 1997, Report prepared for the health technology assessment panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales, Br. J. Urol., 79, 1 Dearnaley, 1999, Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party, BJU Int., 83, 18, 10.1046/j.1464-410x.1999.00905.x Von Eschenbach, 1997, American Cancer Society guideline for the early detection of prostate cancer: update 1997, CA Cancer J. Clin., 47, 261, 10.3322/canjclin.47.5.261 Coley, 1997, Screening for prostate cancer. Clinical Guideline: Part III, Ann. Intern. Med., 126, 480, 10.7326/0003-4819-126-6-199703150-00011 Prostate cancer awareness for men. www.auanet.org. www.cancernet.nci.nih.gov. Questions and answers about the PSA test. 1996 Mandelson, 1995, PSA screening: a public health dilemma, Annu. Rev. Public Health, 16, 283, 10.1146/annurev.pu.16.050195.001435 Lange, 1997, Is screening for prostate cancer the current gold standard?—Yes, Eur. J. Cancer, 33, 354 Kramer, 1997, Is screening for prostate cancer the current gold standard?—No, Eur. J. Cancer, 33, 348 Adami, 1994, Ethics of a prostate cancer screening trial, Lancet, 343, 958, 10.1016/S0140-6736(94)90071-X Jacobsen, 1995, Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing, JAMA, 271, 1445, 10.1001/jama.274.18.1445 Mercer, 1997, Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization and future intentions, Can. J. Public Health, 88, 327, 10.1007/BF03403900 Beemsterboer, 2000, Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European Randomized Study of Screening for Prostate Cancer, Rotterdam, J. Urol., 164, 1216, 10.1016/S0022-5347(05)67144-3 1999, Rationale for randomised trials of prostate cancer screening, Eur. J. Cancer, 35, 262, 10.1016/S0959-8049(98)00379-7 Fair, 1997, Cancer of the prostate: a nutritional disease?, Urology, 50, 840, 10.1016/S0090-4295(97)00339-7 Fleshner, 1998, Diet, androgens, oxidative stress and prostate cancer susceptibility, Cancer Metastasis Rev., 17, 325, 10.1023/A:1006118628183 Burack, 1999, Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness, Med. Clin. North Am., 83, 1423, 10.1016/S0025-7125(05)70173-5 Walsh, 1997, Family history facilitates the early diagnosis of prostate carcinoma, Cancer, 80, 1871, 10.1002/(SICI)1097-0142(19971101)80:9<1871::AID-CNCR28>3.0.CO;2-1 Kupelian, 1997, Familial prostate cancer: a different disease?, J. Urol., 158, 2197, 10.1016/S0022-5347(01)68194-1 Smith, 1996, Racial differences in a prostate cancer screening study, J. Urol., 156, 1366, 10.1016/S0022-5347(01)65588-5 Henderson, 1997, Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer, J. Natl. Cancer Inst., 89, 134, 10.1093/jnci/89.2.134 Morgan, 1996, Age-specific reference ranges for serum prostate-specific antigen in black men, N. Engl. J. Med., 335, 304, 10.1056/NEJM199608013350502 Smith, 1997, Racial differences in operating characteristics of prostate cancer screening tests, J. Urol., 158, 1861, 10.1016/S0022-5347(01)64147-8 Epstein, 1993, Correlation of pathologic findings with progression after radical retropubic prostatectomy, Cancer, 71, 3582, 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y Lu-Yao, 1993, An assessment of radical prostatectomy. Time trends, geographic variation and outcomes. The Prostate Patient Outcome Research Team, JAMA, 269, 2633, 10.1001/jama.269.20.2633 Schmidt, 1986, Trends in patterns of care for prostate cancer, 1974–1983: results of survey by the American College of Surgeons, J. Urol., 136, 416, 10.1016/S0022-5347(17)44889-0 Miller, 1993, What is the role of early detection and screening in cancer control?, J. Public Health Policy, 14, 403, 10.2307/3342875 Hall, 1996, Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?, Sem. Urol. Oncol., 14, 122 Coley et al., 1997 (Ref. [1]), p. 402. Collins, 1996, Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate, JAMA, 276, 1976, 10.1001/jama.276.24.1976 Wilson, 1968 Hulka, 1988, Cancer screening. Degrees of proof and practical application, Cancer, 62, 1776, 10.1002/1097-0142(19881015)62:1+<1776::AID-CNCR2820621314>3.0.CO;2-V Goel, 2001, Appraising organized screening programs for genetic susceptibility testing, Br. Med. J., 322, 1174, 10.1136/bmj.322.7295.1174 Budenholzer, 1995, Prostate-specific antigen testing to screen for prostate cancer, J. Fam. Pract., 41, 270 Godley, 1999, Prostate cancer screening: promise and peril—a review, Cancer Detect. Prev., 23, 316, 10.1046/j.1525-1500.1999.99033.x Woolf, 1997, Prostate cancer: to screen or not to screen?, Oncology, 11, 447 Welch, 2000, Are increasing 5-y survival rates evidence of success against cancer?, JAMA, 283, 2975, 10.1001/jama.283.22.2975 Sakr, 1993, The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J. Urol., 150, 379, 10.1016/S0022-5347(17)35487-3 2000, 47 W. Sakr, N. Pernick, C. Butler, H. Nassar, V. Pansare, D. Grignon, The prevalence of high grade, clinically occult prostatic adenocarcinoma and its relationship to high grade PIN, Abstract 656, American Urological Association, July 2000. Nam, 1998, Prostate cancer: 2. Natural history, CMAJ, 159, 685 Rosen, 1995, Impact of prostate-specific antigen screening on the natural history of prostate cancer, Urology, 46, 757, 10.1016/S0090-4295(99)80339-2 Dennis, 2000, Analysis of recent trends in prostate cancer incidence and mortality, Prostate, 42, 247, 10.1002/(SICI)1097-0045(20000301)42:4<247::AID-PROS1>3.0.CO;2-5 Coley, 1997, Early detection of prostate cancer: Part I. Prior probability and effectiveness of tests, Ann. Intern. Med., 126, 394, 10.7326/0003-4819-126-5-199703010-00010 Brawer, 2000, Screening for prostate cancer, Sem. Surg. Oncol., 18, 29, 10.1002/(SICI)1098-2388(200001/02)18:1<29::AID-SSU5>3.0.CO;2-Y Catalona, 1994, Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men, J. Urol., 151, 1283, 10.1016/S0022-5347(17)35233-3 Cooner, 1990, Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen, J. Urol., 143, 1146, 10.1016/S0022-5347(17)40211-4 Chodak, 1989, Progress and problems in screening for carcinoma of the prostate [Review], World J. Surg., 13, 60, 10.1007/BF01671155 Faul, 1982, Experience with the German annual preventive checkup examination Gilbertsen, 1971, Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease, JAMA, 215, 81, 10.1001/jama.215.1.81 Jenson, 1960, Evaluation of annual examination in the detection of cancer: special reference to cancer of the gastrointestinal tract, prostate, breast, and female reproductive tract, JAMA, 174, 1783, 10.1001/jama.1960.03030140005002 Lee, 1988, Prostate cancer: comparison of transrectal US and digital rectal examination for screening, Radiology, 168, 389, 10.1148/radiology.168.2.3293108 McWhorter, 1992, A screening study of prostate cancer in high risk families, J. Urol., 148, 826, 10.1016/S0022-5347(17)36733-2 Mettlin, 1994, Relative sensitivity and specificity of serum prostate specific antigen (PSA) concentration compared with age referenced PSA, PSA density and PSA change, Cancer, 74, 1615, 10.1002/1097-0142(19940901)74:5<1615::AID-CNCR2820740520>3.0.CO;2-6 Mueller, 1988, An evaluation of serial digital rectal examinations in screening for prostate cancer, J. Urol., 140, 1445, 10.1016/S0022-5347(17)42069-6 Thompson, 1987, Impact of routine screening for adenocarcinoma of the prostate on stage distribution, J. Urol., 137, 424, 10.1016/S0022-5347(17)44055-9 Vihko, 1985, Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurement of serum acid phosphatase compared, Cancer, 56, 173, 10.1002/1097-0142(19850701)56:1<173::AID-CNCR2820560127>3.0.CO;2-0 Waaler, 1988, Digital rectal examination to screen for prostatic cancer, Eur. Urol., 15, 34, 10.1159/000473390 Flanigan, 1994, Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer, J. Urol., 152, 1506, 10.1016/S0022-5347(17)32457-6 Bunting, 1999, Is there still a role for prostatic acid phosphatase? CSCC position statement, Clin. Biochem., 32, 591, 10.1016/S0009-9120(99)00068-5 Oesterling, 1991, Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J. Urol., 145, 907, 10.1016/S0022-5347(17)38491-4 Polascik, 1999, Prostate specific antigen: a decade of discovery—what we have learned and where we are going, J. Urol., 162, 293, 10.1016/S0022-5347(05)68543-6 Pannek, 1998, The use of percent free prostate specific antigen for staging clinically localized prostate cancer, J. Urol., 159, 1238, 10.1016/S0022-5347(01)63571-7 Dorr, 1993, An evaluation of prostate-specific antigen as a screening test for prostate cancer, Arch. Intern. Med., 153, 2529, 10.1001/archinte.153.22.2529 Catalona, 1981, Measurement of prostate specific antigen in serum as a screening test for prostate cancer, N. Engl. J. Med., 324, 1156, 10.1056/NEJM199104253241702 Puppo, 1992, Comparison between digital rectal examination, prostate specific antigen and transrectal ultrasound in symptomatic patients, Eur. Urol., 21, 87, 10.1159/000474899 Marcus, 1990, Detection of prostate cancer by digital rectal exam, prostate specific antigen, and transrectal ultrasonography, J. Urol., 143, 313A Brawer, 1989, Serum prostate specific antigen and prostate pathology in men having simple prostatectomy, Am. J. Clin. Pathol., 92, 760, 10.1093/ajcp/92.6.760 Babaian, 1992, The relationship of prostate specific antigen to digital rectal examination and transrectal ultrasonography, Cancer, 69, 1195, 10.1002/cncr.2820690521 Babaian, 1991, Early detection program for prostate cancer: results and identification of high-risk population, Urology, 37, 193, 10.1016/0090-4295(91)80283-D Cooner, 1988, Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer, J. Urol., 139, 758, 10.1016/S0022-5347(17)42624-3 Muschenheim, 1991, Screening for carcinoma of the prostate with prostate specific antigen, Ann. Clin. Lab. Sci., 21, 371 Brawer, 1992, Screening for prostatic carcinoma with prostate specific antigen, J. Urol., 147, 841, 10.1016/S0022-5347(17)37401-3 Vallancien, 1991, Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination, J. Urol., 146, 1308, 10.1016/S0022-5347(17)38076-X Partin, 1996, The use of prostate-specific antigen and free/total prostate specific antigen in the diagnosis of localized prostate cancer, Urol. Clin. NA, 23, 531, 10.1016/S0094-0143(05)70333-5 Cooner, 1990, Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen, J. Urol., 143, 1146, 10.1016/S0022-5347(17)40211-4 Hammerer, 1994, Systematic sextant biopsies in 651 patients referred for prostate evaluation, J. Urol., 151, 99, 10.1016/S0022-5347(17)34880-2 Ellis, 1994, Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography, J. Urol., 52, 1500 Catalona, 1993, Detection of organ-confined prostate cancer is increased through prostate specific antigen based screening, JAMA, 270, 948, 10.1001/jama.270.8.948 Stamey, 1995, Second Standard Conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994, Urology, 45, 173, 10.1016/0090-4295(95)80001-8 Rafferty, 2000, Reference reagents for prostate-specific antigen (PSA): establishment of the First International Standards for free PSA and PSA (90:10), Clin. Chem., 46, 1310, 10.1093/clinchem/46.9.1310 Chan, 2000, WHO First International Standards for prostate-specific antigen: the beginning of the end for assay discrepancies?, Clin. Chem., 46, 1291, 10.1093/clinchem/46.9.1291 Gann, 1995, A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer, JAMA, 273, 289, 10.1001/jama.273.4.289 Carter, 1999, Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines, Urology, 54, 780, 10.1016/S0090-4295(99)00271-X Polascik, 1999, Prostate specific antigen: a decade of discovery—what we have learned and where we are going, J. Urol., 162, 293, 10.1016/S0022-5347(05)68543-6 Zlotta, 1998, Etiology and diagnosis of prostate cancer: what's new?, Eur. Urol., 33, 351, 10.1159/000019615 Kamoi, 1999, Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer, Sem. Oncol., 26, 140 Diamandis, 2000, Trends Endocrinol. Metab., 11, 54, 10.1016/S1043-2760(99)00225-8 Becker, 2000, Clinical value of human glandular kallikrein and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen concentrations 3.0 ng/mL or greater, Urology, 55, 694, 10.1016/S0090-4295(99)00585-3 Oesterling, 1993, Serum prostate-specific antigen in a community-based population of healthy men, JAMA, 270, 860, 10.1001/jama.270.7.860 Carter, 1992, Longitudinal evaluation of prostate-specific antigen concentrations in men with and without prostate diseases, JAMA, 267, 2215, 10.1001/jama.267.16.2215 Bunting, 1995, A guide to the interpretation of serum prostate specific antigen concentrations, Clin. Biochem., 28, 221, 10.1016/0009-9120(95)91342-Z Veltri, 1999, Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations, Urology, 53, 736, 10.1016/S0090-4295(98)00617-7 Bangma, 1997, Free and total prostate-specific antigen in a screened population, Br. J. Urol., 79, 756, 10.1046/j.1464-410X.1997.00130.x Woodrum, 1998, Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer, J. Urol., 159, 5, 10.1016/S0022-5347(01)63996-X Brawer, 1999, Complexed PSA: the wave of the future, Rev. Urol., 1, 27 Jung, 2000, Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?, Clin. Chem., 46, 55, 10.1093/clinchem/46.1.55 Brawer, 2000, Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer, J. Urol., 163, 1476, 10.1016/S0022-5347(05)67646-X Cartledge, 1999, The stability of free and bound prostate-specific antigen, BJU Int., 84, 810, 10.1046/j.1464-410x.1999.00311.x Catalona, 2000, Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial, Urology, 55, 372, 10.1016/S0090-4295(99)00547-6 Finne, 2000, Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network, Urology, 56, 418, 10.1016/S0090-4295(00)00672-5 Ross, 1999, Rational PSA screening strategies for prostate cancer: computer simulations of age ranges, PSA cutoffs, and testing intervals (abstract), J. Urol., 161, 210, 10.1097/00005392-199904010-00841 Carter, 1997, Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer, JAMA, 277, 1456, 10.1001/jama.277.18.1456 Smith, 1996, Longitudinal screening for prostate cancer with prostate-specific antigen, JAMA, 276, 1309, 10.1001/jama.276.16.1309 Ellis, 1994, Diagnosis of prostatic carcinoma: the yield of serum prostate-specific antigen, digital rectal examination and transrectal ultrasound, J. Urol., 152, 1520, 10.1016/S0022-5347(17)32460-6 Keetch, 1994, Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values, J. Urol., 151, 1571, 10.1016/S0022-5347(17)35304-1 Levine, 1998, Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer, J. Urol., 159, 471, 10.1016/S0022-5347(01)63951-X Naughton, 2000, A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection, J. Urol., 164, 388, 10.1016/S0022-5347(05)67367-3 Zlotta, 1996, Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with isolated prostatic intraepithelial neoplasia, Eur. Urol., 30, 249, 10.1159/000474176 Slavin, 1995, Screening for prostate cancer: an analysis of the early experience, CA Cancer J. Clin., 45, 134, 10.3322/canjclin.45.3.134 Epstein, 1994, Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer, JAMA, 271, 368, 10.1001/jama.271.5.368 Hoedemaeker, 1997, Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer, World J. Urol., 15, 339, 10.1007/BF01300181 Hoedemaeker, 2000, Histopathological prostate cancer characteristics at radical prostatectomy after population based screening, J. Urol., 164, 411, 10.1016/S0022-5347(05)67373-9 Mettlin, 1996, The results of a five-y early prostate cancer detection intervention, Cancer, 77, 150, 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3 Svetec, 1998, PSA screening—current controversy, Ann. Oncol., 9, 1283, 10.1023/A:1008446208963 Roberts, 2000, Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997, J. Urol., 163, 1471, 10.1016/S0022-5347(05)67645-8 Schroder, 1993, Screening for prostate cancer—necessity or nonsense?, Eur. J. Cancer, 29A, 656, 10.1016/S0959-8049(05)80339-9 Alhara, 1994, Heterogeneity of prostate cancer in radical prostatectomy specimens, Urology, 43, 60, 10.1016/S0090-4295(94)80264-5 Orozco, 1998, Positive biopsy rate consistently increases with age at the same prostate-specific antigen concentration in patients with normal digital rectal examination, Urology, 51, 531, 10.1016/S0090-4295(98)00003-X Carter, 1999, The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non-palpable disease, Urology, 53, 126, 10.1016/S0090-4295(98)00466-X Bostwick, 1994, Staging of prostate cancer, Sem. Surg. Oncol., 10, 60, 10.1002/ssu.2980100110 Babaian, 1995, Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability, J. Urol., 154, 1808, 10.1016/S0022-5347(01)66790-9 Stamey, 2000, Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens, J. Urol., 163, 1155, 10.1016/S0022-5347(05)67713-0 Partin, 1997, Combination of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological stage of localized prostate cancer, JAMA, 277, 1445, 10.1001/jama.277.18.1445 Virtanen, 1999, Estimation of prostate cancer probability by logistic regression: free and total prostate specific antigen, digital rectal examination and heredity are significant variables, Clin. Chem., 45, 987, 10.1093/clinchem/45.7.987 Garruto, 2000, Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy, Tech. Urol., 6, 60 Habib, 1996, Molecular and cellular biology of the prostate: is it clinically relevant?, Br. J. Urol., 78, 546, 10.1046/j.1464-410X.1996.13210.x Bookstein, 1997, Tumor-suppressor genes in prostatic oncogenesis: a positional approach, Br. J. Urol., 79, 28, 10.1111/j.1464-410X.1997.tb00798.x Alers, 2000, Identification of genetic markers for prostatic cancer progression, Lab. Invest., 80, 931, 10.1038/labinvest.3780096 Chan, 1998, Plasma insulin-like growth factor and prostate cancer risk: a prospective study, Science, 279, 563, 10.1126/science.279.5350.563 Yang, 1998, Low p27 expression predicts poor disease-free survival in patients with prostate cancer, J. Urol., 159, 941, 10.1016/S0022-5347(01)63776-5 Witte, 2000, Genome wide scan for prostate cancer aggressiveness loci, Am. J. Hum. Genet., 67, 92, 10.1086/302960 Lange, 1999, Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX, Clin. Cancer Res., 5, 4013 Xu, 2000, Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics, Am. J. Hum. Genet., 66, 945, 10.1086/302807 Elgamal, 2000, Prostate-specific membrane antigen (PSMA): current benefits and future value, Sem. Surg. Oncol., 18, 10, 10.1002/(SICI)1098-2388(200001/02)18:1<10::AID-SSU3>3.0.CO;2-V Su, 2000, Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction, Sem. Surg. Oncol., 18, 17, 10.1002/(SICI)1098-2388(200001/02)18:1<17::AID-SSU4>3.0.CO;2-7 Bostwick, 2000, Prognostic factors in prostate cancer. College of American Pathologists consensus statement 1999, Arch. Pathol. Lab. Med., 124, 995, 10.5858/2000-124-0995-PFIPC Fowler, 2000, Comparison of recommendations of urologists and radiation oncologists for treatment of clinically localized prostate cancer, JAMA, 283, 3217, 10.1001/jama.283.24.3217 Lu-Yao, 1997, Population based study of long term survival in patients with clinically localised prostate cancer, Lancet, 349, 906, 10.1016/S0140-6736(96)09380-4 Wasson, 1993, A structured literature review of treatment for localized prostate cancer, Arch. Fam. Med., 2, 487, 10.1001/archfami.2.5.487 Svetec, 1998, PSA screening—current controversy, Ann. Oncol., 9, 1283, 10.1023/A:1008446208963 Goldenberg, 1998, Prostate cancer: 6. Surgical treatment of localized disease, CMAJ, 159, 1265 Warde, 1998, Prostate cancer: 7. Radiation therapy for localized disease, CMAJ, 159, 1381 Krahn, 1994, Screening for prostate cancer. A decision analytic view, JAMA, 272, 773, 10.1001/jama.272.10.773 Fleming, 1993, A decision analysis of alternative treatment strategies for clinically localized prostate cancer, JAMA, 269, 2650, 10.1001/jama.269.20.2650 Smith, 2000, Quality-of-life outcomes for men with prostate carcinoma detected by screening, Cancer, 88, 1454, 10.1002/(SICI)1097-0142(20000315)88:6<1454::AID-CNCR25>3.0.CO;2-S Donnell, 1999, Prostate cancer: a challenge for screening, Surg. Oncol. Clin. NA, 8, 693, 10.1016/S1055-3207(18)30183-2 Rietbergen, 1999, The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study, J. Urol., 161, 1192, 10.1016/S0022-5347(01)61630-6 Sandblom, 2000, Prostate carcinoma trends in three counties in Sweden 1987–1996. Results from a population-based national cancer register, Cancer, 88, 1445, 10.1002/(SICI)1097-0142(20000315)88:6<1445::AID-CNCR24>3.0.CO;2-T Horninger, 2000, Prostate cancer screening in the Tyol, Austria: experience and results, Eur. J. Cancer, 36, 1322, 10.1016/S0959-8049(00)00113-1 Bartsch, 2000, Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyol, Austria, J. Urol., 163, 88 Meyer, 1999, Downward trend in prostate cancer mortality in Quebec and Canada, J. Urol., 161, 1189, 10.1016/S0022-5347(01)61628-8 Legler, 1998, The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the U.S., Cancer, Causes Control, 9, 519, 10.1023/A:1008805718310 Bunting, 1998, Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer, Clin. Biochem., 31, 501, 10.1016/S0009-9120(98)00052-6 Hankey, 1999, Cancer surveillance series: interpreting trends in prostate cancer: Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates, J. Natl. Cancer Inst., 91, 1017, 10.1093/jnci/91.12.1017 Etzioni, 1999, Cancer surveillance series: interpreting trends in prostate cancer: Part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality, J. Natl. Cancer Inst., 91, 1033, 10.1093/jnci/91.12.1033 Pearson, 1996, Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer, Urology, 48, 4, 10.1016/S0090-4295(96)00603-6 de Koning, 1998, PSA screening for prostate cancer: the current controversy, Ann. Oncol., 9, 1293, 10.1023/A:1008428327309 Optenberg, 1990, Economics of screening for carcinoma of the prostate, Urol. Clin. NA, 17, 719, 10.1016/S0094-0143(21)01367-7 Littrup, 1994, Prostate cancer screening. Appropriate choices?, Cancer, 74, 2016, 10.1002/1097-0142(19941001)74:7+<2016::AID-CNCR2820741705>3.0.CO;2-J Coley, 1997, Early detection of prostate cancer. Part II: Estimating the risks, benefits and costs, Ann. Intern. Med., 126, 468, 10.7326/0003-4819-126-6-199703150-00010 Grover, 2000, The economic burden of prostate cancer: forecasts from the Montreal Prostate Model, CMAJ, 162, 977 Benoit, 1997, The economics of prostate cancer screening, Oncology, 11, 1533 Krahn, 1999, Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen, CMAJ, 160, 49 Grover, 1999, Prostate cancer: 12. The economic burden, CMAJ, 160, 685 Hoffman, 1996, Attitudes and practices of primary care physicians for prostate cancer screening, Am. J. Prev. Med., 12, 277, 10.1016/S0749-3797(18)30325-8 Hansen, 1995, Attitudes of European urologists to early prostatic carcinoma II. Attitude to therapy and to screening examinations, Eur. Urol., 28, 196, 10.1159/000475051 O'Connor, 1999, Decision aids for patients facing health treatment or screening decisions: systematic review, Br. Med. J., 319, 731, 10.1136/bmj.319.7212.731 Feldman-Stewart, 2000, What questions do patients with curable prostate cancer want answered?, Med. Decis. Making, 20, 7, 10.1177/0272989X0002000102 Wolf, 1996, The impact of informed consent on patient interest in prostate-specific antigen screening, Arch. Intern. Med., 156, 1333, 10.1001/archinte.156.12.1333 Volk, 1999, A randomized controlled trial of shared decision making for prostate cancer screening, Arch. Fam. Med., 8, 333, 10.1001/archfami.8.4.333 Handley, 1994, The use of prostate specific antigen for prostate cancer screening: a managed care perspective, J. Urol., 152, 1689, 10.1016/S0022-5347(17)32362-5 www.moh.gov.on.ca. www.healthdialogue.com. Greiver, 2000, PSA screening: a view from the front lines, CMAJ, 162, 789 Elhilali, 2000, PSA screening: the bottom line, CMAJ, 162, 791 Walther, 1995, Prostate cancer screening. Why the controversy?, Adv. Urol. Oncol., 4, 315